Key Summary Points {#FPar1}
==================

Silymarin-Eurosil 85 is a formulation of silymarin with high oral bioavailability and potent antioxidant effects in preclinical models of liver disease.Silymarin acts as a free radical scavenger, along with modulating the enzymes responsible for the development of cellular damage, fibrosis and cirrhosis.Clinically, silymarin reduces liver dysfunction, may reduce liver-related mortality in patients with cirrhosis and improves glycemic control in patients with concomitant diabetes, with few if any adverse events.By reducing oxidative stress and consequent cytotoxicity, silymarin protects intact liver cells or cells not yet irreversibly damaged and thus may be considered to be hepatoprotective.For maximum benefit, silymarin should be initiated as early as possible in patients with fatty liver disease when the regenerative potential of the liver is still high.

Introduction {#Sec1}
============

Worldwide, approximately 2 million people a year die as a result of liver diseases, with cirrhosis (the 11th most common cause of mortality) causing approximately 1.16 million of these deaths \[[@CR1]\]. In Western industrialized countries, the leading causes of cirrhosis are now alcohol and non-alcoholic fatty liver disease (NAFLD), while hepatitis B is still one of the main causes in many Asian counties \[[@CR1]\].

The therapeutic use of natural components has received considerable attention in the last 2 decades. *Silybum marianum* (milk thistle) has been safely used for centuries as a natural herbal medicine for the treatment of liver disorders. The bioactive extract of milk thistle, silymarin, has well-documented antioxidant and hepatoprotective properties in preclinical studies \[[@CR2]--[@CR7]\]. A number of silymarin formulations are available, including Legalon^®^, which contains the Eurosil 85^®^ formulation that has high oral bioavailability and well-characterized pharmacokinetic and pharmacodynamic properties. Most clinical data discussed in this review have been obtained using the Legalon^®^ formulation. The aim of the current narrative review is to describe the pharmacologic features of silymarin extract and to review the data surrounding its use as supportive treatment in patients with liver diseases.

Compliance with Ethics Guidelines {#Sec2}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Silymarin Pharmacology {#Sec3}
======================

Chemistry {#Sec4}
---------

Silymarin is an extract from the dried seeds and fruits of the milk thistle plant (*S. marianum*). Milk thistle has been used medicinally in Europe since the first century AD. Its medicinal properties were mentioned in the writings of the Greek physician and botanist Dioscorides (40--90 AD), who recommended it as a treatment for snakebite \[[@CR8], [@CR9]\]. The sixteenth century English herbalist Nicholas Culpeper recommended milk thistle for jaundice and for expelling stones \[[@CR9]\]. By the nineteenth century, a German scientist, Johannes Gottfried Rademacher, had shown that extracts or 'tinctures' from milk thistle seeds were beneficial for treating patients with liver disorders \[[@CR9], [@CR10]\].

The milk thistle extract silymarin is a complex mixture of plant-derived compounds identified as mostly flavonolignans, flavonoids (taxifolin, quercetin) and polyphenolic molecules \[[@CR11]\]. These compounds are known to be antioxidants in addition to having several other biologic properties \[[@CR12]\]. The four main flavonolignan isomers in silymarin are silibinin, isosilibinin, silichristin and silidianin, but the most prevalent and biologically active of these is silibinin (also called silybin). Approximately 50--60% of the silymarin complex is silibinin, with the other flavonolignan isomers comprising about 35%: silichristin (\~ 20%), silidianin (\~ 10%) and isosilibinin (\~ 5%) \[[@CR13], [@CR14]\].

Silibinin is a polyphenolic flavonoid antioxidant with the molecular formula of C~25~H~22~O~10~ and with a molecular weight of 482.44 g/mol \[[@CR15]\]. Silibinin itself is mixture of two diastereomers, silibinin A and silibinin B, in an approximately equimolar ratio (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR16]\]. It undergoes phase I and phase II biotransformation in the liver. During phase II, multiple conjugation reactions have been observed that include the formation of glucuronide and glucuronide sulfate derivatives \[[@CR11], [@CR17]\].Fig. 1Chemical structure of the silibinin diastereoisomers, silibinin A and silibinin B (C~25~H~21~O~10~)

Silymarin was first isolated in 1968 by German scientists at the University of Munich and then described and patented by the German herbal medicine manufacturer Madaus as a specific treatment "against liver diseases" \[[@CR10]\]. The first commercial preparation of silymarin was developed by Rottapharm/Madaus (Cologne, Germany) and complies with the analytical specifications reported in the European Pharmacopoeia 01/2005 under "Milk Thistle fruit." It is registered as a drug for liver diseases in many countries in Europe, Asia, America, Africa and Australia. Different forms, including capsules and tablets, are available with different dosages; the recommended daily dosage (depending on the commercial formulation used) is between 420 and 600 mg, and the majority of clinical trials have been conducted with a dosage of 140 mg three times a day.

Pharmacokinetics {#Sec5}
----------------

Crude silymarin extract is lipophilic and poorly soluble in water, so only about 20--50% is absorbed from the gastrointestinal tract after ingestion \[[@CR18], [@CR19]\]. For this reason, formulation scientists have endeavored to improve the oral bioavailability and solubility of silymarin preparations, but the commercially available silymarin-containing products differ significantly in their content, dissolution and oral bioavailability of the active ingredient silibinin \[[@CR20]\]. In 1995, Rottapharm/Madaus invented a co-precipitation processing method that produced a high-quality silymarin (90--96% purity; approximately 60% of the content being silibinin) with an enhanced dissolution profile (\> 90% of silibinin liberated by the co-precipitate); this advanced processing method was subsequently patented in 2014 under the trade name Eurosil 85^®^ \[[@CR20]--[@CR22]\]. Most of the published clinical research on silymarin has used this standardized pharmaceutical preparation.

The silymarin formulation derived using the Eurosil 85^®^ extraction method contains 60% silibinin and has a bio-dissolution of up to 85%. Therefore, the commercially available silymarin capsule, at a daily dosage of 3 capsules, provides 420 mg of silymarin, corresponding to 250 mg of silibinin \[[@CR23]\].

Silymarin from this specific orally administered formulation is rapidly absorbed; the peak plasma concentration of silibinin is reached about 2--4 h after oral administration, and its plasma half-life is approximately 6 h \[[@CR23]\]. It has been established that 3--7% of orally administrated silibinin is excreted in an unchanged form in the urine \[[@CR24]\]. After gastrointestinal absorption silibinin and the other components of silymarin are rapidly metabolized by phase I and phase II biotransformation reactions in liver cells \[[@CR11]\] and undergo extensive enterohepatic circulation \[[@CR23]\]: about 80% of silibinin is excreted as glucuronide and sulfate conjugates with bile \[[@CR25], [@CR26]\]. It is assumed that 20--40% of bile silibinin is recovered, whereas the remaining part is excreted via feces \[[@CR27], [@CR28]\].

Silymarin was assessed for drug--drug interaction and for cytochrome P450 (CYP450) induction or inhibition by permeability studies with Caco-2 cells and by studies with human primary hepatocytes and with human liver microsomes, respectively \[[@CR29]\]. At a supratherapeutic concentration (1 µmol/l), there was negligible inhibition of the CYP450 enzymes 1A2, 2A6, 2B6, 2C8, 2C9 and 2E1, minor (\< 20%) inhibition of CYP 3A4 and moderate (\< 40%) inhibition of CYP 2C19 and 2D6. The authors concluded that, since the therapeutic concentration of silibinin is \~ 0.2 µmol/l, silymarin is unlikely to cause hepatic drug--drug interactions at the standard dose \[[@CR29]\]. Results of trials in healthy volunteers and/or clinical trials suggest that milk thistle does not affect CYP 1A2, 2C9, 2D6, 2E1, 3A4 or 3A5 \[[@CR30]\]. In two multiple-dose pharmacokinetic studies, silymarin (160--450 mg every 8 h) did not reduce levels of the CYP 3A4 substrate indinavir \[[@CR30]\]. However, as our knowledge in this area is incomplete, patients taking silymarin along with CYP450 enzyme substrates should be advised to watch for signs of drug--drug interactions \[[@CR30]\].

Because silymarin has been shown to lower elevated blood glucose and hemoglobin A1c levels in patients with diabetes, there is theoretical potential for an additive risk of hypoglycemia in patients taking antidiabetic drugs \[[@CR30]\]. However, there is no documented hypoglycemia and no clinical evidence of this additive effect. Other theoretical drug interactions with silymarin, based on laboratory/animal studies, include inference with estrogen therapy (in animal studies, silymarin binds to estrogen receptor beta), reduced clearance of glucuronidated drugs (in laboratory studies, milk thistle inhibited uridine diphosphoglucuronosyl transferase) and increased absorption of P-glycoprotein substrates (in vitro, milk thistle can inhibit P-glycoprotein activity) \[[@CR30]\]. Silymarin and silibinin have the potential to interact with statins; in vitro they inhibit both organic anion transporting polypeptide 1B1 (transports statins into the liver) and breast cancer resistance protein (transports statins from the liver to the bile) \[[@CR30]\]. However, silymarin (140 mg, 3 times a day) did not alter the pharmacokinetics of a single 10-mg dose of rosuvastatin in a study in healthy males \[[@CR30]\]. In a trial in hepatically impaired renal transplant patients, silymarin reduced the apparent clearance of the immunosuppressant sirolimus \[[@CR30]\].

Pharmacodynamics {#Sec6}
----------------

Several pharmacologic actions of silibinin have been identified including antioxidant properties, anti-inflammatory properties, antifibrotic effects and insulin resistance modulation.

### Antioxidant Properties {#Sec7}

The production of reactive oxygen species (ROS) is a natural consequence of a variety of essential biochemical reactions in the liver, mostly related to the processes involved in detoxification. Exposure to high levels of toxins (e.g., alcohol, hepatotoxic drugs) or intensive oxidation of free fatty acids (i.e., insulin resistance) leads to abnormal production of ROS; the endogenous antioxidants may also become depleted. For example, it is widely acknowledged that ethanol promotes the formation of various free radicals in several cell types, including hepatocytes, Kupffer cells, endothelial cells and infiltrating inflammatory leukocytes \[[@CR31]\]. The consequent imbalance, with persistent presence of ROS that are not neutralized by endogenous antioxidants, creates a condition called "oxidative stress", which is implicated in the pathogenesis of a variety of liver disorders including liver fibrosis \[[@CR32]\].

In vitro, silibinin is found to be a potent scavenger of ROS, such as hydroxyl and peroxyl anions and hypochlorous acid, in various model systems, such as rat liver microsomes \[[@CR6]\], as well as human platelets, leukocytes, endothelial cells \[[@CR33]\], erythrocytes \[[@CR34]\] and fibroblasts \[[@CR35]\]. In addition, superoxide anion radicals and nitric oxide were inhibited in isolated Kupffer cells after treatment with silibinin (concentration at which 50% inhibition occurs of 80 μmol/l) \[[@CR2]\].

Silymarin may augment the generation of glutathione in the liver via an increase in substrate availability (i.e. cysteine) for its biosynthesis, which subsequently contributes to the enhancement of its antioxidant capacity in liver tissues \[[@CR3]\].

Silymarin protects liver cells by a number of mechanisms. First, it stabilizes membrane permeability through inhibition of lipid peroxidation, thereby helping the liver to maintain levels of its own protective antioxidant, glutathione \[[@CR3]\]. Silymarin also protects against injury from various toxic chemicals such as carbon tetrachloride \[[@CR36]\], for example, by inhibiting the production of tumor necrosis factor-alpha (TNF-α), interferon-gamma, interleukin (IL)-2 and IL-4 \[[@CR36], [@CR37]\] as a consequence of blocking hepatic nuclear factor kappa B (NFκ~B~) activation \[[@CR36], [@CR38]\]. Silymarin is able to reduce the cellular uptake of xenobiotics, including mushroom poisons, by blocking organic ion uptake transporters on the surface of hepatocytes \[[@CR39]\]. It also inhibits TNF-α expression, for example, when induced by α-amanitin toxin from poisonous mushrooms \[[@CR40]\]. The hepatoprotective properties of silibinin are widely attributed to these antioxidant activities \[[@CR41]\].

### Anti-Inflammatory Properties {#Sec8}

Chronic inflammation has been associated with progressive hepatic fibrosis and the development of cirrhosis \[[@CR42]\], and oxidative stress may be the common underlying mechanism in the initiation and progression of hepatic inflammation in various liver disorders \[[@CR10]\]. NF-κB is an important transcriptional regulator of the inflammatory response and plays an essential role in regulating inflammatory signaling pathways in the liver \[[@CR43]\]. Moreover, NF-κB is activated in virtually every chronic liver disease, including AFLD \[[@CR44]\], NAFLD \[[@CR45]\], viral hepatitis \[[@CR46]\] and biliary liver disease \[[@CR47], [@CR48]\]. There is increasing evidence that demonstrates the overall inhibition by silymarin of inflammatory mediators such as NF-κB and inflammatory metabolites (e.g., prostaglandin E2 \[PGE~2~\] and leukotriene B~4~ \[LTB~4~\]) \[[@CR49]\].

Kupffer cells are resident liver macrophages that appear to be involved in innate immune responses and host defense through the expression and secretion of inflammatory mediators \[[@CR50]\]. In isolated rat Kupffer cells, silymarin weakly inhibited PGE~2~ formation but strongly inhibited LTB~4~ formation, even at low concentrations (15 μmol/l) \[[@CR2]\]. This selective inhibition of LTB~4~ formation by Kupffer cells and possibly other cell types may account for the anti-inflammatory potential of silymarin.

### Antifibrotic Effects {#Sec9}

Silibinin has demonstrated antifibrogenic effects in animal and in vitro models \[[@CR38], [@CR49], [@CR51]\]. Hepatic fibrogenesis, which results from chronic liver tissue damage, is characterized by activation of hepatic stellate cells (HSCs), a liver-specific type of pericyte. Activated HSCs develop into myofibroblasts, which are responsible for the deposition of collagen fibers leading to liver cirrhosis. In an in vitro model of human hepatic fibrogenesis, silibinin demonstrated antifibrogenic properties by dose-dependently inhibiting the growth factor-induced production of pro-collagen in activated human HSC \[[@CR38]\].

The antifibrogenic effect of silymarin has also been confirmed in an animal model of alcohol-induced hepatic fibrosis in non-human primates receiving chronic treatment with alcohol \[[@CR49]\]. In this study, baboons were fed alcohol (50% of daily calories) for 3 years with a nutritionally adequate diet, which resulted in an increase of collagen type I in hepatic biopsy samples. Results showed that concomitant administration of silymarin significantly reduced the alcohol-induced increase in hepatic collagen type I (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR49]\].Fig. 2Levels of collagen type 1 in hepatic biopsy samples from baboons fed a diet containing 50% alcohol, with or without concomitant silymarin \[[@CR49]\]. SEM: standard error of the mean. ^a^*P* \< 0.05 vs. alcohol.Reproduced with permission from Lieber et al. \[[@CR49]\]

### Modulation of Insulin Resistance {#Sec10}

Insulin resistance is widely recognized as the key mechanism in the pathogenesis of NAFLD. In a rat model of NAFLD, silibinin ameliorated insulin resistance by reducing visceral obesity, enhancing lipolysis and inhibiting gluconeogenesis \[[@CR52]\].

Clinical Effects of Silymarin {#Sec11}
=============================

Liver Cirrhosis/Alcohol-Related Liver Disease {#Sec12}
---------------------------------------------

Fatty liver disease (FLD) is caused by the accumulation of excess fat in the liver, which can lead to serious liver disease for many people. In individuals who consume too much alcohol, alcoholic fatty liver disease (AFLD) is the earliest stage of alcoholic-related liver disease \[[@CR53], [@CR54]\]. Silymarin has been investigated in a number of clinical studies in patients with liver cirrhosis and/or alcohol-related liver disease (Table [1](#Tab1){ref-type="table"}) \[[@CR55]--[@CR63]\]. Six of these clinical trials were conducted in patients affected by liver cirrhosis (mainly alcohol-related) \[[@CR55]--[@CR60]\]. Four studies examined the impact of silymarin on clinical outcomes such as mortality \[[@CR55], [@CR57], [@CR58], [@CR60]\], and two of these trials had survival as the primary clinical endpoint \[[@CR55], [@CR57]\]. The impact of silymarin in these studies is shown in Table [2](#Tab2){ref-type="table"}, with the study by Ferenci et al. showing a significant impact on mortality \[[@CR55]\]. This was a double-blind, prospective, randomized study that was performed to determine the effect of silymarin (Eurosil 85^®^-derived formulation) on the outcome of patients with cirrhosis \[[@CR55]\]. Of the 170 patients with cirrhosis, 87 were treated with silymarin 420 mg/day (alcoholic: 47, non-alcoholic: 40), and 83 received placebo (alcoholic: 45, non-alcoholic: 38) for at least 24 months, with a median observation period of 41 months. In the placebo group, there were 32/39 liver-related deaths, whereas in the silymarin group 16/28 patient deaths were related to liver disease. In this study, the 4-year survival rate was significantly higher (58% vs. 39%) in silymarin recipients than placebo recipients (*P* = 0.036) \[[@CR55]\]. Subgroup analyses found that treatment reduced mortality in patients with alcoholic cirrhosis (*P* = 0.01) and in patients with less severe cirrhosis (class A disease according to the Child-Turcotte criteria \[[@CR64]\]) (*P* = 0.03).Table 1Clinical trials with silymarin in patients with liver cirrhosis and/or alcoholic liver diseaseReferencesCondition*n*Treatment (*n*)DurationOutcome with silymarinSalmi et al. \[[@CR61]\]Liver disease (78% with daily alcohol use)97Silymarin 420 mg/day (47)Placebo (50)4 weeksImprovement in ALT, AST, liver function parameters and liver histologyTrinchet et al. \[[@CR58]\]ALD (50% with cirrhosis)116Silymarin 420 mg/day (57)Placebo (59)3 monthsNo significant effectFerenci et al. \[[@CR55]\]ALD or NAFLD (70% with cirrhosis)170Silymarin^a^ 420 mg/day (87)Placebo (59)Median 41 monthsImprovement in 4-year survival; survival differences most marked in patients with ALD and cirrhosis, and those with low severity disease (Child class A)Feher et al. \[[@CR62]\]ALD36Silymarin^a^ (17)Placebo (19)6 months↓ in ALT, AST, bilirubin and procollagen synthesisMuzes et al. \[[@CR63]\]ALDNASilymarin^a^ 420 mg/dayPlacebo6 monthsImprovement of anti-oxidative systems (↓ in MDA, ↑ in GSH)Bunout et al. \[[@CR60]\]ALD (72% with cirrhosis)59Silymarin^a^ 280 mg/day (25)Placebo (34)15 monthsNo effect on clinical course or mortality, or liver functionVelussi et al. \[[@CR59]\]Insulin-treated T2DM with alcoholic cirrhosis60Silymarin^a^ 600 mg/day + standard treatment (30)Standard treatment only (30)12 monthsImprovement in blood glucose (including fasting), HbA1c and MDA, and ↓ in daily insulin requirement↓ in ALT and ASTPares et al. \[[@CR57]\]ALD with cirrhosis200Silymarin^a^ 450 mg/day (103)Placebo (97)2 yearsNo effect on progression of liver disease or survivalLucena et al. \[[@CR56]\]ALD with cirrhosis49Silymarin^a^ 450 mg/day (24)Placebo (25)6 months↓ MDA and aminoterminal propeptide of procollagen type III*ALD* alcoholic liver disease, *ALP* alkaline phosphatase, *ALT* alanine transaminase, *AST* aspartate aminotransferase, *GGT* gamma-glutamyl transferase, *GSH* glutathione, *HbA1c* glycosylated hemoglobin, *MDA* methylenedioxyamphetamine, *NA* not available, *NAFLD* non-alcoholic fatty liver disease, *T2DM* type 2 diabetes mellitus^a^Silymarin formulation using the Eurosil 85^®^ processTable 2Studies investigating the impact of silymarin on survival in patients with cirrhosisData from \[[@CR13]\], adapted with permission from Saller et al. \[[@CR13]\]ReferencesSilymarin dose (mg/day)*n*Patient/disease characteristicsTreatment duration (mo)Liver-related mortalitySilymarin (% patients)Placebo (% patients)Ferenci et al. \[[@CR55]\]420170Liver cirrhosis etiology: alcoholic/non-alcoholic 92/78Child classification: A, 89; B, 69; C, 122418.4^a^37.3Trinchet et al. \[[@CR58]\]420116Alcoholic hepatitis, 58 with cirrhosisBaseline histology scores: fibrosis, 3; alcoholic hepatitis, 531.85.1Bunout et al. \[[@CR60]\]28071Alcoholic hepatic insufficiency (24/29 patients with biopsy data had cirrhosis)1513.212.2Pares et al. \[[@CR57]\]450200Alcoholic cirrhosisChild classification (Silymarin/Placebo): A, 37.9%/24.7%; B, 51.5%/62.9%; C, 6.8%/7.2%249.414.6Total Saller et al. (systematic review) \[[@CR13]\]280--450545--3--2410.0^a^17.3^a^*P* \< 0.01 vs. placebo

In another similar randomized controlled trial by Pares et al. \[[@CR57]\], survival was investigated in patients receiving the specific Eurosil 85^®^-derived oral formulation of silymarin or placebo over 2 years. The mortality rate was 14.6% in the silymarin group and 14.4% in the placebo group (not statistically significant over this shorter duration of treatment). However, in a subgroup analysis of patients with a diagnosis of hepatitis C (29/75 patients), no deaths occurred in the silymarin group (0/13) while 4/16 patients in the placebo group died (*P* = 0.06) \[[@CR57]\].

A review of clinical data with silymarin calculated the overall odds ratio for liver-related mortality in the silymarin versus placebo groups across the five studies as 0.53 (i.e., 47% risk reduction; 95% confidence intervals 0.33--0.86) \[[@CR13]\]. In this analysis, the pooled liver-related mortality rate was 4.9% per year in patients receiving silymarin compared with 9.3% per year in patients receiving placebo \[[@CR13]\]. This review also noted that in one of the studies, the proportion of patients requiring hospital admission because of liver-related complications was lower in those receiving silymarin than in those receiving placebo (10.0% vs. 16.3%; *P* \< 0.01) \[[@CR60]\]. Therefore, the lack of an effect of silymarin on survival in three of the four studies with death as an outcome \[[@CR57], [@CR58], [@CR60]\] may have been because the trials were underpowered, not long enough or included too many patients with severe/advanced disease to be able to demonstrate an impact on mortality. A Cochrane review of trials in patients with alcoholic and/or viral liver disease found that, compared with placebo or no intervention, milk thistle significantly reduced liver-related mortality in all reviewed trials, but not when the analysis was limited to high-quality trials \[[@CR65]\]. Further large-scale studies are warranted to clarify the effect of silymarin on liver-related mortality.

Where liver function was examined, silymarin consistently demonstrated a reduction in liver enzyme levels \[alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels\] compared with placebo \[[@CR60]--[@CR62]\]. For example, in a randomized study in 97 patients with histologically diagnosed mild, acute and subacute liver disease induced by alcohol abuse, silymarin treatment for 4 weeks resulted in a significantly greater improvement in liver function, as evidenced by a decrease in ALT and AST levels, compared with placebo \[[@CR61]\].

Several studies also demonstrated an improvement in oxidative stress parameters \[[@CR56], [@CR59], [@CR63]\]. For example, a double-blind, placebo-controlled study in patients with chronic alcoholic liver disease showed that 6 months of treatment with silymarin (Eurosil 85^®^-derived formulation) significantly restored the antioxidant defense system, as indicated by the following: increased superoxide dismutase activity of erythrocytes and lymphocytes, increased free-SH group serum levels and increased glutathione peroxidase activity (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR63]\]. In a 12-month randomized controlled study, 60 insulin-treated diabetic patients with alcoholic cirrhosis were treated with either silymarin 600 mg/day plus standard therapy or standard therapy (control group) \[[@CR59]\]. The aim of this study by Velussi et al. \[[@CR59]\] was to ascertain whether long-term treatment with silymarin was effective in reducing lipoperoxidation and insulin resistance in diabetic patients with liver cirrhosis. Results showed that silymarin effectively neutralized excess superoxides and reduced systemic signs of inflammation (C-peptide levels) \[[@CR59]\]. In addition to reducing membrane peroxidation, silymarin also significantly reduced levels of glycosylated hemoglobin and insulin requirements (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR59]\].Fig. 3Effect of silymarin on antioxidant capacity \[[@CR63]\]. This was measured by serum levels of free sulfhydryl groups and glutathione peroxidase activity in erythrocytes and lymphocytes in patients with alcohol-induced liver disease receiving silymarin or placebo. SH: sulfhydryl; GSH-Px: glutathione peroxidase. ^a^*P* \< 0.05 vs. month 0; ^b^*P* \< 0.05 vs. placebo \[[@CR63]\]Fig. 4Changes in alcoholic liver disease and diabetes parameters in patients with diabetes and alcoholic liver disease receiving standard treatment alone (untreated) or with concomitant silymarin (treated) \[[@CR59]\]. **a** Plasma malondialdehyde levels (a marker of membrane peroxidation); **b** glycosylated hemoglobin; **c** average daily insulin dose. ^a^*P* \< 0.05 vs. untreated control group; ^b^*P *\< 0.01 vs. untreated control group.Reproduced with permission from Velussi et al. \[[@CR59]\]

NAFLD and Non-Alcoholic Steatohepatitis {#Sec13}
---------------------------------------

NAFLD is another major cause of chronic liver disease in the absence of significant alcohol consumption and is frequently associated with insulin resistance, central obesity, type-2 diabetes and dyslipidemia \[[@CR42], [@CR66]\]. Due to the exploding prevalence of these comorbidities, NAFLD is recognized as a major worldwide health problem and the leading cause of liver disease in Western countries with a prevalence up to 33% \[[@CR67]\]. There is also an increasing prevalence of NAFLD in Eastern countries, reflecting the increasing incidence of obesity and obesity-related diseases in these regions \[[@CR68]\].

NAFLD encompasses a wide spectrum of disorders, ranging from benign fat accumulation (simple steatosis), with or without varying degrees of hepatic inflammation (steatohepatitis), to progressive fibrosis and ultimately to cirrhosis and end-stage liver disease \[[@CR66], [@CR69]\]. Approximately 20% of patients with NAFLD (simple steatosis) will go on to develop the more severe form known as non-alcoholic steatohepatitis (NASH) \[[@CR70]\].

To date, the combination of dietary modifications and increased physical activity remains the mainstay of NAFLD management \[[@CR71]\]. Unfortunately, however, many patients find instituting lifestyle changes difficult over the long term \[[@CR72]\].

Oxidative stress is regarded as the key pathogenic component involved in the progression of simple steatosis to NASH \[[@CR73]\]. Endogenous antioxidants function as direct scavengers of ROS and are thus able to either delay or prevent oxidative stress as well as other parameters of hepatocyte damage \[[@CR74]--[@CR76]\]. Glutathione is the most abundant cellular antioxidant that protects hepatocytes against the toxic effects of ROS \[[@CR77], [@CR78]\]. Recent literature strongly suggests that treatment with antioxidant agents and other putative free radical scavengers is beneficial in improving biochemical and histologic parameters in NASH \[[@CR67], [@CR79]\].

Use of vitamin E as an antioxidant has led to controversial results; it has been investigated as a treatment for NASH or NAFLD in two large randomized clinical trials \[[@CR80], [@CR81]\]. Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in adult patients with NASH, but only at a very high dosage (533.6 mg/day for 96 weeks) \[[@CR81]\]. Use at such high dosage over a prolonged period has raised concerns about the long-term safety of vitamin E, particularly in patients with NAFLD who have not yet progressed to NASH \[[@CR71]\]. The widespread use of vitamin E in all NAFLD patients is not currently recommended and should be limited to non-diabetic patients with biopsy-proven NASH \[[@CR71]\].

Silymarin (Eurosil 85^®^-derived formulation) has been studied as a treatment option for NAFLD and NASH (Table [3](#Tab3){ref-type="table"}) \[[@CR79], [@CR82], [@CR83]\]. The pilot study by Butorova et al. was conducted in patients with either NAFLD or NASH, who were treated for 2 months with diet only or with silymarin \[[@CR82]\]. These results indicated that silymarin was able to reduce or normalize liver function parameters (transaminase levels) and improve ultrasound parameters of liver anatomy \[[@CR82]\].Table 3Clinical studies with silymarin in patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitisReferencesCondition (*n*)*n*Treatment (*n*)DurationOutcomeButorova et al. \[[@CR82]\]NAFLD (20) or NASH (50)70Silymarin^a^ 420 mg/day (35)Nonpharmacological therapy (35)2 months↓ in transaminases and lipid parameters, and improvement in subjective well-being vs. controlGillessen et al. \[[@CR92]\]NAFLD190Silymarin^a^ 280--420 mg/day (190)4 monthsImprovement in liver function parameters and quality of life vs. baselineSorrentino et al. \[[@CR83]\]NAFLD and metabolic syndrome78Silymarin^a^ 420 mg/day + vitamin E (43)No additional treatment (35)90 daysImprovement in biometric parameters (↓ in abdominal circumference, BMI), size of right liver lobe by ultrasound measurement, and in both the HSI and LAP indicesWah Keong et al. \[[@CR79]\]NASH99Silymarin^a^2100 mg/day (49)Placebo (50)48 weeksImprovement in liver histology, noninvasive markers of hepatic fibrosis, and liver function parameters vs. baseline with silymarin, but not with placebo*BMI* body mass index, *HSI* hepatic steatosis index, *LAP* lipid accumulation product, *NAFLD* non-alcoholic fatty liver disease, *NASH* non-alcoholic steatohepatitis^a^Silymarin formulation using the Eurosil 85^®^ process

Another study involved patients with NAFLD treated for 3 months with either diet or diet plus a novel formulation of silymarin plus vitamin E in a dietary supplement \[[@CR83]\] (same daily posology of silymarin as Silymarin-Eurosil 85^®^). Validated indices of liver steatosis (e.g., lipid accumulation product, hepatic steatosis index) were used as outcome parameters. Results showed significant improvements of both indices together with improvements in biometric parameters (e.g., abdominal circumference, body mass index) in the group receiving silymarin/vitamin E compared with the placebo group. These findings suggest that, in patients with uncomplicated NAFLD, for whom the standard treatment would be limited to diet and exercise only, the use of silymarin/vitamin E as a dietary adjunct is potentially more effective than diet alone and may possibly improve patient motivation to sustain lifestyle changes over time \[[@CR83]\].

Since pilot studies showed only a trend towards improvement when patients with NASH were treated with the commercial (Eurosil 85^®^) formulation of silymarin at the currently approved dosage of 420 mg/day, another clinical study was conducted with a higher dosage of silymarin. Previous phase I studies had shown that silymarin was safe at doses of up to 2100 mg/day, so this dosage was chosen to treat patients with biopsy-confirmed NASH for 48 weeks in a randomized, double-blind, placebo-controlled trial \[[@CR79]\]. Although no statistically significant difference was reached for the primary endpoint \[≥ 30% improvement from baseline in the NASH and NAFLD Activity Score (NAS) on liver biopsy\], significantly more patients in the silymarin than the placebo group had a measurable improvement in fibrosis (Fig. [5](#Fig5){ref-type="fig"}a). In addition, there were more patients with fibrosis improvement or resolution of fibrosis in the silymarin group, and the change in liver stiffness favored silymarin (change in liver stiffness − 0.7 vs. 6.0 kPa), although between-group differences were not significant \[[@CR79]\]. Improvements in noninvasive markers of fibrosis (AST to platelet ratio index, fibrosis-4 score and NAFLD fibrosis score) were observed in the group receiving silymarin but not in the group receiving placebo (Fig. [5](#Fig5){ref-type="fig"}b) \[[@CR79]\].Fig. 5Effect of 48 weeks' treatment with silymarin 2100 mg/day in 99 patients with histologically proven non-alcoholic steatohepatitis \[[@CR79]\]. A proportion of patients with: a NAS score improvement (defined as ≥ 30% improvement in NAS), fibrosis improvement (defined as a ≥ 1 point improvement in the histologic component of the NAS score), resolution of fibrosis (defined as absence of fibrosis at EOT) or development of cirrhosis \[[@CR79]\]. ^a^*P* \< 0.05 vs. placebo; ^b^line charts illustrating the changes in the (i) APRI, (ii) FIB-4 score and (iii) NAFLD fibrosis scores in the silymarin and placebo groups \[[@CR79]\]. *APRI* aspartate aminotransferase to platelet ratio index, *EOT* end of treatment, *FIB-4* fibrosis-4, *NAFLD* nonalcoholic fatty liver disease, *NAS* NASH and NAFLD activity score, *NASH* non-alcoholic steatohepatitis.Part B of figure reproduced with permission from Wah Kheong et al. \[[@CR79]\]

Amatoxin-Induced Liver Failure {#Sec14}
------------------------------

The ingestion of amatoxin-containing mushrooms may result in hyperacute liver failure, depending on the ingested dose \[[@CR84], [@CR85]\]. Amatoxin is known to inhibit RNA polymerase II \[[@CR85]\], which is essential for hepatocyte function. Therefore, amatoxin is used experimentally as a toxic model for liver failure. Although no prospective studies on the use of silymarin for amatoxin-induced liver failure in mushroom poisoning can be designed, abundant clinical evidence shows that parenteral use of a silibinin-based formulation may be considered as the treatment of choice in this setting \[[@CR84], [@CR86]\]. Early diagnosis and prompt initiation of intravenous therapy are crucial.

Drug-Induced Liver Injury {#Sec15}
-------------------------

It is well known that many drugs undergo hepatic metabolism and can induce, directly or through their active metabolites, hepatotoxicity. As has been observed with anti-tuberculosis drugs (ATDs), this may result in increased morbidity or mortality \[[@CR87]\]. Hepatotoxicity may necessitate treatment discontinuation, drug interruption and substitution or dose adjustment \[[@CR87]\]. Drug-induced liver injury (DILI) is still the most common cause of acute liver failure in Western societies \[[@CR88]\].

Previous studies have reported that certain herbal drugs, phytochemicals and food supplements can prevent and reduce the hepatotoxicity of different drugs \[[@CR89]\].

Several trials have investigated the effectiveness of silymarin in preventing DILI from ATDs. In a prospective, multicenter trial, patients (*N* = 565) were randomized to receive ATDs and silibinin capsules (70 mg, 3 times a day) or ATDs only \[[@CR90]\]. After 8 weeks of therapy, there were no significant differences between patients receiving silibinin and controls in the number of patients with liver injury (2.2% vs. 2.4%), diagnosed with DILI (7.2% vs. 9.3%) or who had ATD treatment that was suspended because of liver injury and symptoms (3.25% vs. 6.19%). However, fewer patients in the silibinin group experienced the liver injury symptoms anorexia and nausea (*P* \< 0.05) \[[@CR90]\]. In contrast, in another smaller trial (*N* = 55), after 4 weeks of treatment the incidence of ATD DILI was 3.7% with silymarin compared with 32.1% with placebo \[[@CR91]\]. The decline in levels of the antioxidant enzyme superoxide dismutase was also significantly lower with silymarin than placebo, and the authors attributed the lower risk of liver injury to superoxide dismutase restoration \[[@CR91]\]. A recent meta-analysis, which included a total of 1198 patients from five randomized controlled trials \[*n* = 585 (silymarin); *n* = 613 (placebo)\] concluded that prophylactic therapy with silymarin contributed to a noticeably reduced risk of development of ATD DILI 4 weeks after the initiation. In addition, silymarin significantly improved liver function, measured by a reduction in ALT, AST and alkaline phosphatase levels, in patients who were receiving ATDs \[[@CR87]\].

The commercial (Eurosil 85^®^) formulation of silymarin significantly improved the signs and symptoms of hepatotoxicity in a real-world observational German study that assessed its effect on liver function and quality of life patients with possible DILI (*n* = 190) \[[@CR92]\]. Quality of life was rated by patients on a 6-point Likert scale from 1 to 6 (corresponding with slightly impaired to very strongly impaired). Liver enzyme levels were significantly reduced after ≥ 2 months' silymarin treatment; liver-related symptoms and quality of life also improved (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR92]\].Fig. 6Changes in liver enzymes, liver-related symptoms and quality of life in patients with non-alcoholic liver disease receiving silymarin for 4 months \[[@CR92]\]. **a** Liver function parameters (all comparisons *P* \< 0.001 baseline vs. 4 months); **b** signs and symptoms of liver disease; **c**: quality of life. *ALT* alanine aminotransferase, *AP* alkaline phosphatase, *AST* aspartate aminotransferase, *GGT* gamma-glutamyl transferase, *TBIL* total bilirubin.Reproduced with permission from Gillessen et al. \[[@CR92]\]

Agents used for cancer chemotherapy are very frequently associated with DILI. For this reason, patients who receive chemotherapy require careful liver function assessment prior to treatment to determine the most appropriate choice of chemotherapeutic agent and whether dose modification is required \[[@CR93]\]. In a study in China, patients with acute lymphoblastic or acute myeloid leukemia undergoing chemotherapy (*n* = 70) received either the Eurosil 85^®^-derived formulation of silymarin (420 mg/day) plus diammonium glycyrrhizinate or diammonium glycyrrhizinate alone \[[@CR94]\]. A greater proportion of silymarin recipients had either no DILI or mild DILI than those who had not received silymarin (measured according to the 1990 Paris International Consensus Conference classification of liver injury) (Fig. [7](#Fig7){ref-type="fig"}) \[[@CR94]\]. Prevention \[[@CR95]\] and treatment \[[@CR96]\] of chemotherapy-induced liver disease using silymarin-based formulations were also evaluated in two pilot studies in pediatric patients with acute lymphoblastic leukemia (*n* = 50 \[[@CR96]\], *n* = 80 \[[@CR95]\]). Positive results were obtained with silymarin treatment for improvement in liver enzyme profiles \[[@CR95], [@CR96]\], providing preliminary evidence that, despite study limitations, silymarin may be a safe and effective supportive-care agent in patients receiving chemotherapy \[[@CR96]\].Fig. 7Preventive effect on DILI by treatment with the combination of silymarin (420 mg/day) plus diammonium glycyrrhizinate compared with diammonium glycyrrhizinate alone in patients with acute lymphoblastic or acute myeloid leukemia undergoing chemotherapy \[[@CR94]\]. DILI was measured according to the 1990 Paris International Consensus Conference classification of liver injury. *Chemo* chemotherapy, *DILI* drug-induced liver injury, *Glyc* diammonium glycyrrhizinate, *Sil* silymarin

Viral Hepatitis {#Sec16}
---------------

Because there are safe and effective direct antiviral treatments available, the use of silymarin for this indication has not been extensively investigated. Nevertheless, studies suggest silymarin may have a role as supportive treatment for patients with acute or chronic hepatitis \[[@CR97]--[@CR99]\]. It should be noted that silymarin is approved for liver support, not for treatment of viral hepatitis.

In a pre-planned analysis, data on baseline silymarin use were collected for patients enrolled in the large HALT-C (Hepatitis C Antiviral Long-Term Treatment against Cirrhosis) trial; the primary aim of the trial was to assess the long-term use of peginterferon alpha-2a in hepatitis C patients with advanced fibrosis or cirrhosis in whom standard care had failed \[[@CR97]\]. Patients were assessed for disease progression (defined as a ≥ 2-point increase in Ishak fibrosis score) at 1.5 and 3.5 year biopsies and followed up for \> 8.65 years for clinical outcomes. At baseline, 17% of the 1049 patients had formerly used silymarin (median treatment duration 6 months), and 16% were still using silymarin (median duration 35 months). Although silymarin use had no effect on clinical outcomes, baseline use/former use was significantly associated with less histologic liver disease progression, and current use of silymarin at baseline was also associated with a significantly lower hepatic collagen content in biopsies \[[@CR97]\]. In another trial in patients with chronic hepatitis C, 177 Egyptian patients received either the commercial (Eurosil 85^®^) formulation of silymarin (125 mg) or a low-dose multivitamin supplement three times a day \[[@CR99]\]. At a 12-month follow-up, patients from both groups had significant (*P* \< 0.05) improvements from baseline in symptoms of fatigue and weight loss, and silymarin users also had significant improvements in vomiting/heart burn. Although not significant, complaints of jaundice and dark urine decreased from 5.8 to 7.4%, respectively, at baseline to 0% and 1.4% at 12 months in silymarin recipients. Patients in both groups had significant improvements from baseline in almost all quality of life (QOL) scores (assessed using the 36-item short-form health survey, modified to include parameters specific to chronic liver disease), with the exceptions being the social functioning score in the silymarin group and the role emotional score in the multivitamin group. As symptom and QOL improvements were observed in both groups, it is possible that they were related to improved health care (regular nurse home visits and medical care) in a community that generally has limited access to these services \[[@CR99]\]. The commercial (Eurosil 85^®^) formulation of silymarin (140 mg/three times a day) has also been assessed in an 8-week randomized, placebo-controlled trial in Egyptian patients with symptoms of acute viral hepatitis (including ALT levels \> 2.5 the upper limit of normal) \[[@CR98]\]. Compared with placebo recipients, those receiving silymarin had significantly faster resolution of biliary retention symptoms of dark urine, jaundice and scleral icterus as well as a significant reduction in indirect bilirubin at day 56; there were no significant between-group differences in changes in other indicators of hepatocellular damage \[[@CR98]\].

Toxicity and Safety {#Sec17}
===================

In clinical trials, silymarin has been used for up to 4 years at doses of up to 420 mg/day (recommended dose) and for up to 48 weeks at 2100 mg/day \[[@CR30]\]. Overall, silymarin and silibinin are well tolerated with only minor adverse events reported \[[@CR13]\]. Results of systematic reviews of clinical trials of silymarin show a low incidence of adverse events (\< 4%, slightly lower than with placebo) and no treatment-related serious adverse events \[[@CR13], [@CR65], [@CR100]\] or deaths \[[@CR13], [@CR100]\]. In placebo-controlled trials in a total of almost 600 patients, the proportion of patients discontinuing treatment because of adverse events was very low (0.68%) and similar to placebo (0.67%); the most commonly reported (≥ 1% of patients) adverse events in these trials were headaches and pruritus, both of which occurred in \< 1.5% of patients \[[@CR100]\]. In open-label trials in a total of \> 3500 patients, gastrointestinal adverse events (diarrhea, dyspepsia, irregular stools and nausea) were among the most commonly reported; however, all occurred in \< 0.25% of patients \[[@CR100]\].

In a randomized, phase I dose ascending trial, 32 patients with non-cirrhotic chronic hepatitis C received placebo, the recommended dose of the commercial (Eurosil 85^®^) formulation of silymarin (140 mg) or one of three higher doses (280 mg, 560 mg or 700 mg) every 8 h for 7 days \[[@CR23]\]. Of the 24 patients who received silymarin, 1 in the 240 mg group reported adverse events (mild-to-moderate nausea and headache, both of which resolved within 24 h and were judged to be unrelated to treatment). In another randomized trial, 177 Egyptian patients with chronic hepatitis C received either the commercial (Eurosil 85^®^) formulation of silymarin (125 mg) or a low-dose multivitamin supplement three times a day \[[@CR99]\]. Twelve-month follow-up data were available for 141 patients. The most commonly reported adverse events (\> 1 event per person week) were abdominal colic/discomfort (3.6 events per person week for silymarin vs. 3.2 for multivitamins), fatigue (3.5 vs. 4.4), headache (3.3 vs. 3.8) and diarrhea (1.4 vs. 1.7 events per person week). No patients in either group discontinued treatment because of adverse events \[[@CR99]\].

In case reports of adverse events, there have been no deaths and only one serious adverse event considered probably related to silymarin \[[@CR100]\]. In this case, a 57-year-old woman required hospitalization after experiencing intermittent sweating, nausea, colicky pain, diarrhea, vomiting, weakness and collapse \[[@CR100]\]. Mild laxative effects have also been reported in patients taking milk thistle preparations \[[@CR30], [@CR101]\]. There have been rare reports of anaphylactic reactions in patients taking milk thistle, one in a patient receiving a standardized preparation \[[@CR102]\] and one in an individual who ingested a tea prepared from Fructus Silybi Mariae (non-standardized preparation) \[[@CR101]\]. Thus, caution is advised in patients with a known sensitivity to plants in the Asteraceae/Compositae family (members of this family include chrysanthemums, daisies, marigolds and ragweed) \[[@CR30], [@CR102]\].

Conclusions {#Sec18}
===========

Silymarin has shown positive effects as supportive treatment in most forms of liver disease including cirrhosis and liver damage due to alcohol abuse. In clinical trials that included patients with cirrhosis, there was a significant reduction of liver-related deaths with silymarin treatment \[[@CR13]\]. The mechanism of action by which silymarin produces these clinical effects is attributed to its antioxidant activity. It exerts an antioxidant effect by acting as a scavenger of the free radicals that induce lipid peroxidation as well as influencing the enzyme systems associated with the cellular damage that leads to fibrosis and cirrhosis.

By reducing oxidative stress and the consequent cytotoxicity, silymarin protects intact liver cells or cells not yet irreversibly damaged and thus may be considered hepatoprotective. This effect was evident in a study of diabetic patients with mild cirrhosis, in which silymarin reduced signs of hepatic dysfunction and improved glycemic control. Therefore, while silymarin can support liver functionality, even in the more advanced stages of fatty liver disease, for maximum benefit, treatment with silymarin should be initiated as early as possible in patients with fatty liver disease (AFLD or NAFLD) or DILI when the regenerative potential of the liver is still high and when removal of oxidative stress, the cause of cytotoxicity, can achieve the best results.
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